Lomecel-B Becomes First Agent to Gain Regenerative Medicine Advanced Therapy Designation for Alzheimer Disease

In a phase 2 trial, the agent met its primary end point of safety, with slowing of disease worsening in patients with mild AD.:

Source: Neurology Read More